Subscribe to GlobalData Explorer to access actionable intelligence spanning 22 industries, 200+ economies and 700k+ companies on a single platform

South Korea: Five largest Private Equity/Venture Financing deals by value in the Pharmaceuticals sector (LTM June 2022)

  • A total of 63 Private Equity/Venture Financing deals (pending and completed) were announced in the Pharmaceuticals of South Korea, in the last twelve months resulting in a total deal value of over $2,601.1 million. In the LTM period, August 2021 turned out to be the most prolific in terms of deal size, with a total deal value of $1,591.1 million, resulting in an average deal value of $176.8 million during that month. On the other hand, the month of June 2021 was the most prolific in terms of deal volume, recording a total of 10 deals, resulting in an average deal value of $18.7 million during that month.

  • Of the 63 deals, the deal secured between CBC Group and Hugel Inc, was the largest Private Equity/Venture Financing deal in the South Korea Pharmaceuticals sector, which was valued at $1,500.0 million and was completed on August 27, 2021. The second-largest deal was between Atinum Investment Co Ltd; Daily Partners Co., Ltd.; KB Investment Co Ltd; Korea Investment Partners Co Ltd; Quad Investment Management Corp; SG Private Equity and LegoChem Biosciences Inc, while the third-largest deal was between Atinum Investment Co Ltd; Imm Investment Corp; InterVest Co., Ltd.; KB Investment Co Ltd; KDB Investment Co Ltd and Orum Therapeutics Inc. The Atinum Investment Co Ltd; Daily Partners Co., Ltd.; KB Investment Co Ltd; Korea Investment Partners Co Ltd; Quad Investment Management Corp; SG Private Equity-LegoChem Biosciences Inc deal and the Atinum Investment Co Ltd; Imm Investment Corp; InterVest Co., Ltd.; KB Investment Co Ltd; KDB Investment Co Ltd-Orum Therapeutics Inc deal were valued at $140.8 million and $54.0 million, respectively. The fourth-largest deal was between DS Asset Management; Korea Investment & Securities Co Ltd; Kudos Ventures; Praxis Capital Partners-D&D Pharmatech Co Ltd valued at $51.0 million, whereas the deal between Chong Kun Dang Holdings Corp; Daily Partners Co., Ltd.; E&Venture Partners; Imm Investment Corp; LSK Investment Inc; NHN Investment Co.,Ltd.; SBI Investment Korea Co Ltd; Smilegate Investment Inc; Stick Ventures; Withwin Investment Association 50-Biorchestra Co Ltd valued at $45.4 million was the fifth-largest deal.

  • Cumulatively, the top five deals amounted to $1,791.2 million and accounted for nearly 68.86% of the total deals (by value) announced during the last twelve months.

South Korea: Five largest Private Equity/Venture Financing deals by value in the Pharmaceuticals sector (LTM June 2022)

Published: June 2022
Source: GlobalData



Explore, track and compare industries, economies and companies in a single platform through GlobalData Explorer.​

Single License $700 per month (billed Annually)
Multiple Licenses Connect with a GlobalData representative to discover our offers for multiple licenses​
  • 700K+Companies
  • 22Industries
  • 15K+Reports
  • 200+Countries & Regions
Still looking?

Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.

Explorer

Access more premium companies when you subscribe to Explorer